Novo Nordisk’s diabetes drug Ozempic and its weight-loss version Wegovy, both containing semaglutide, have been linked to a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION).
Recent studies, including one published in JAMA Ophthalmology, show that diabetic patients taking semaglutide may be 4.28 times more likely to develop NAION, while overweight or obese patients face a 7.64 times higher risk compared to those using other medications. NAION reduces blood flow to the optic nerve, causing sudden and irreversible blindness in some cases.
Although the overall risk is low, research points to the need for careful monitoring of eye health while using these drugs. Previous studies have also linked semaglutide to diabetic retinopathy, especially in those with poorly managed diabetes. These findings suggest more research is needed to understand how the drug might contribute to vision problems and what can be done to reduce the risk.
Semaglutide has also been associated with gastrointestinal issues, like gastroparesis and pancreatitis, raising concerns about its broader safety. Natural alternatives, such as berberine and polyphenol-rich foods like berries and green tea, may help regulate blood sugar and promote weight loss without these risks. For those considering Ozempic or Wegovy, it’s important to weigh the benefits against the possible long-term side effects.
SOURCE:
Source: Original Article
Publish Date: